Financial Statements

Karyopharm Therapeutics Inc. (KPTI)


-0.10 (-8.00%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) -1,179-1,070-873-674-
Net Income -165-124-196-200-178
Stock Dividends -15---495
Dividend Paid -----
Retained Earnings -1,344-1,179-1,070-873-674

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 2234-
Annual Depreciation 65-1-16
Capital Expenditure -0-6-0-0-2
Net PPE 72234

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -----
New Purchases -243-178-275-45-226
Intangible and Goodwill -----

Karyopharm Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Karyopharm Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.